is a principal investigator in the following: Restore-Life VNS registry study funded by LivaNova, ESKETINTRD3004: An open-label, long-term, safety and efficacy study of intranasal esketamine in treatment-resistant depression, The effects of psilocybin on cognitive function in healthy participants, The safety and efficacy of psilocybin in participants with treatment-resistant depression (P-TRD), A double-blind, randomized, parallel-group study with quetiapine extended release as comparator to evaluate the efficacy and safety of seltorexant 20 mg as adjunctive therapy to antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms who have responded inadequately to antidepressant therapy (Janssen), An open-label, long-term, safety and efficacy study of aticaprant as adjunctive therapy in adult and elderly participants with major depressive disorder (MDD) (Janssen), A randomized, double-blind, multicenter, parallel-group, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aticaprant 10 mg as adjunctive therapy in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia and inadequate response to current antidepressant therapy, A study of disease characteristics and real-life standard of care effectiveness in patients with major depressive disorder (MDD) with anhedonia and inadequate response to current antidepressant therapy including an SSRI or SNR (Janssen) as well as UK Chief Investigator for Compass (COMP006 & COMP007 studies) and Novartis MDD study (MIJ821A12201)
Therefore, we reported evidence about blood vessel recruitment and activation (running) toward the site of injury, also described as bypassing occlusion via alternative pathways (Vukojevic et al., 2018
Leucine-tRNA-synthase-2-expressing B cells contribute to colorectal cancer immunoevasion
Please note: Our wellness therapies are designed to complement a healthy lifestyle, not as a replacement for medication
